The deal puts the entire valuation of Syngene International Ltd, a wholly-owned subsidiary of Biocon Ltd, at Rs 3,800 crore.
"This investment reflects Syngene's leading position in the contract research and manufacturing space in Asia, acknowledging its comprehensive multidisciplinary capabilities," Biocon Chairman and Managing Director Kiran Mazumdar-Shaw said in a statement.
This transaction is part of the overall strategic plan for Syngene and sets a new benchmark as we prepare the company for listing, she added.
Post the completion of the transaction, Biocon and BRL will jointly hold 85.54 per cent stake in Syngene, it added.
Also Read
Commenting on the development, IVFA Managing Director Vishal Nevatia said: "We had partnered with Biocon through our first fund in 2003. We are excited to partner with them again...This deal showcases the IVFA investment philosophy of working with high quality entrepreneurs and management teams."
Biocon shares today closed at Rs 499.95 apiece on the BSE, up 2.70 per cent from its previous close.